New Zealand Formulary
Menu Close Menu

Fewer cancers.
Better survival.
Equity for all.

Systemic Anti-Cancer Therapy Regimen Library

Home > LYM NHL B-cell - bendamustine and oBINUTUZumab > LYM - oBINUTUZumab maintenance
This regimen is a component of LYM NHL B-cell - bendamustine and oBINUTUZumab

oBINUTUZumab Maintenance (LYM NHL B-cell - bendamustine and oBINUTUZumab)

Treatment Overview

oBINUTUZumab maintenance starts approximately 2 months after Induction phase dose of oBINUTUZumab.

Continue for up to 2 years, or until disease progression or unacceptable toxicity.

Cycles 1 to 12 - 56 days

Cycle length:
56

loratadine:

  • May be omitted if no infusion-related reaction occurred during the previous infusion.

Intravenous dexamethasone:

  • Must be given if a Grade 3 infusion-related reaction occurred during the previous infusion OR the lymphocyte count > 25 x 109/L prior to next treatment.
  • May be omitted if no or a Grade 1–2 infusion-related reaction occurred during the previous infusion.

oBINUTUZumab: Consider withholding routine anti-hypertensives for 12 hours prior to, during, and for one hour after each oBINUTUZumab infusion.

Cycle details

Cycles 1 to 12 - 56 days

Medication Dose Route Days Max Duration
paracetamol * 1000 mg flat dosing oral administration 1
loratadine * 10 mg oral administration 1
dexamethasone 20 mg flat dosing intravenous 1 15 minutes
oBINUTUZumab 1000 mg flat dosing intravenous 1 6 hours

loratadine:

  • May be omitted if no infusion-related reaction occurred during the previous infusion.

Intravenous dexamethasone:

  • Must be given if a Grade 3 infusion-related reaction occurred during the previous infusion OR the lymphocyte count > 25 x 109/L prior to next treatment.
  • May be omitted if no or a Grade 1–2 infusion-related reaction occurred during the previous infusion.

oBINUTUZumab: Consider withholding routine anti-hypertensives for 12 hours prior to, during, and for one hour after each oBINUTUZumab infusion.

Full details

Cycles 1 to 12 - 56 days

Day: 1

Medication Dose Route Max duration Details
paracetamol * 1000 mg flat dosing oral administration
Instructions:

30 to 60 minutes prior to oBINUTUZumab.
loratadine * 10 mg oral administration
Instructions:

30 to 60 minutes prior to oBINUTUZumab.

  • Omit if no infusion-related reactions occurred during the previous infusion of oBINUTUZumab.
dexamethasone 20 mg flat dosing intravenous 15 minutes
Instructions:

ONE hour prior to oBINUTUZumab, or as per institutional practice.

  • Must be given if a grade 3 infusion-related reaction occurred with the previous infusion OR the lymphocyte count > 25 x 109/L prior to next treatment.
  • Omit in patients with no or a grade 1 or 2 infusion-related reaction during previous infusion.
oBINUTUZumab 1000 mg flat dosing intravenous 6 hours
Instructions:

Consider withholding routine anti-hypertensives for 12 hours prior to, during, and for one hour after oBINUTUZumab infusion.

If NO or a Grade 1 infusion-related reaction occurred during previous infusion and the final infusion rate was ≥ 100 mg/hour:

  • Start at 100 mg/hour. If tolerated, rate can be increased by 100 mg/hour every 30 minutes, to a maximum rate of 400 mg/hour.

If a Grade 2 or higher infusion-related reaction occurred during previous infusion:

  • Start at 50 mg/hour. If tolerated, rate can be increased by 50 mg/hour every 30 minutes to a maximum rate of 400 mg/hour.

Short duration infusion ONLY for patients with follicular lymphoma and NO Grade 3 or higher infusion-related reaction occurred during first cycle (Induction):

  • Start at 100 mg/hour for 30 minutes. If tolerated, increase rate to 900 mg/hour.
  • If an infusion-related reaction of Grade 1-2 with ongoing symptoms, or a Grade 3 or higher occurs with the short duration infusion all subsequent infusions should be given at the standard rates (above).

Supportive Care Factors

Factor Value
Antiviral prophylaxis for hepatitis B virus: Required for anti–HBc positive patients at risk of reactivation
Antiviral prophylaxis for herpes virus: Routine antiviral prophylaxis may be considered
Emetogenicity: Minimal
Hypersensitivity / Infusion related reaction risk: High - routine premedication recommended
Irradiated blood components: Irradiation of blood components is recommended
Pneumocystis jirovecii pneumonia (PJP) prophylaxis: Routine antibiotic prophylaxis may be considered

References

Roche Products (New Zealand) Limited Gazyva® New Zealand data sheet 21 July 2022 https://www.medsafe.govt.nz/profs/datasheet/g/GazyvaInfusion.pdf (accessed 17 October 2023).

* The medicines, doses, combinations, and schedule in this treatment regimen have been carefully reviewed against international best practice guidelines by specialists in medical oncology around New Zealand and this advice has been accepted for publication by Te Aho o Te Kahu (the Cancer Control Agency). Sometimes medicines that are used in routine clinical practice have not been through a formal review process by the NZ Medicines Regulator Medsafe and are therefore considered unapproved or off-label. These medicines are legally able to be prescribed through sections 25 and 29 of the Medicines Act and by obtaining informed consent from patients. All treatment regimens listed on this website have been through robust peer review and are considered an accepted standard of care, whether prescribed through sections 25 or 29 or carrying formal Medsafe Approval.

s29: This symbol indicates that some formulations of the associated medicine are legally only able to be prescribed under section 29 of the Medicines Act. You can see which formulations are section 29 by hovering over the s29 symbol. You can access full medication details from the New Zealand Formulary by clicking on the medication name. Each clinician retains full responsibility for ensuring they have complied with all relevant obligations and requirements of section 29 including obtaining informed patient consent prior to prescribing the applicable medicine.